Oncology M&A Valuation Data

Comparable Transactions / Precedent Deals


Excel spreadsheet with Scope Research's cancer center/oncology M&A valuation data. Transactions segmented by type, which includes radiation therapy, proton therapy, radiosurgery, and medical oncology (mostly radiation therapy centers).


  • 23 transactions with revenue or EBITDA multiples
  • 20 of these deals have EBITDA Multiples
  • Median multiples of 1.6x revenue and 5.5x EBITDA
  • Last updated 6/24/2022


Each transaction includes price to revenue and/or EBITDA multiples. We provide the names of the parties, transaction date, ownership percentage acquired, deal price (stated on a total enterprise value basis), time period of the financial information relied upon, revenue and/or EBITDA, and a description of our source documents and key details related to the financial information presented. 

Visit scoperesearch.co for more information about our firm, process, and healthcare M&A data. Questions? Reach out to will@scoperesearch.co for more information.

All transactions included in the Scope Research healthcare M&A databases are meticulously researched and sourced from public documentation. Our internal records include an audit trail of links to our sources, which include:


  • Fairness opinions
  • SEC filings
  • Press releases
  • Bond market research
  • Medicare cost reports
  • CON filings (FOIA)
  • Form 990s
  • Public audits
  • AG reports
  • Insurance department filings